A Randomised, Single Dose, 5-period, 5-treatment, Crossover Study to Assess the Relative Bioavailability of 4 Different Formulations of Verinurad and Allopurinol in Healthy Subjects

This study is a single centre, randomised, open-label, single-dose, 5-period, 5-treatment, crossover study in healthy male and female subjects. This study is intended to assess the relative bioavailability between the fixed dose combination (FDC, i.e. verinurad/allopurinol FDC capsule 12/300 mg) and free combination formulations of verinurad (i.e. verinurad prolonged release Hydroxypropyl methylcellulose [HPMC] capsule 12 mg) and allopurinol (i.e. allopurinol table 300 mg) in fasted and fed conditions. The study will also assess the relative bioavailability between a formulation only containing verinurad (i.e. verinurad prolonged release gelatin capsule 12 mg) and the FDC capsule.

开始日期2021-04-13

申办/合作机构

AstraZeneca PLC

[+1]

NCT04532918

/ Completed临床1期

An Open-label, 3-Treatment, 3-Period, Fixed Sequence Study in Healthy Subjects to Assess the Pharmacokinetics of Verinurad and Allopurinol When Administered Alone, and in Combination With Single Doses of Cyclosporine or Rifampicin

This Phase 1 study aims to quantify the effects of cyclosporine, a broad transporter inhibitor, and rifampicin, an OATP1B1/3 inhibitor, on verinurad pharmacokinetics (PK). The study is conducted in accordance with Food and Drug Administration guidance on Clinical Drug Interaction Studies, 2020. Verinurad will be developed as a fixed combination since it will always be administered together with allopurinol.

开始日期2020-09-10

申办/合作机构

AstraZeneca PLC

[+1]

NCT04327024

/ Completed临床2期

A Phase 2, Multicentre, Double-Blind, Placebo and Active Control Efficacy and Safety Study to Evaluate Verinurad Combined With Allopurinol in Heart Failure With Preserved Ejection Fraction

International, Multicenter, Double-Blind, Placebo and Active Control Efficacy and Safety Study to Evaluate Verinurad combined with Allopurinol in Heart Failure with Preserved Ejection Fraction

开始日期2020-05-19

申办/合作机构

AstraZeneca PLC

100 项与 Verinurad 相关的临床结果

登录后查看更多信息

100 项与 Verinurad 相关的转化医学

登录后查看更多信息

100 项与 Verinurad 相关的专利（医药）

登录后查看更多信息

项与 Verinurad 相关的文献（医药）

2025-03-24·JACS Au

Structural Basis for Inhibition of Urate Reabsorption in URAT1

Article

作者: Wang, Haijun ; Zhang, Jing ; Lei, Xiaoguang ; Bai, Yingjie ; Ke, Han ; Fan, Junping ; Wang, Jin ; Xie, Wenjun ; Guo, Nianxin

The urate transporter 1 (URAT1) is the primary urate transporter in the kidney responsible for urate reabsorption and, therefore, is crucial for urate homeostasis. Hyperuricemia causes the common human disease gout and other pathological consequences. Inhibition of urate reabsorption through URAT1 has been shown as a promising strategy in alleviating hyperuricemia, and clinical and preclinical drug candidates targeting URAT1 are emerging. However, how small molecules inhibit URAT1 remains undefined, and the lack of accurate URAT1 complex structures hinders the development of better therapeutics. Here, we present cryoelectron microscopy structures of a humanized rat URAT1 bound with benzbromarone, lingdolinurad, and verinurad, elucidating the structural basis for drug recognition and inhibition. The three small molecules reside in the URAT1 central cavity with different binding modes, locking URAT1 in an inward-facing conformation. This study provides mechanistic insights into the drug modulation of URAT1 and sheds light on the rational design of potential URAT1-specific therapeutics for treating hyperuricemia.

2024-10-01·JAMA Cardiology

The AMETHYST Randomized Clinical Trial

Article

作者: Källgren, Christian ; Shah, Sanjiv J. ; Mentz, Robert J. ; Sjöström, C. David ; Voors, Adriaan A. ; Myte, Robin ; Lewis, Gregory D. ; Kitzman, Dalane W. ; Kaguthi, Grace ; Perl, Shira

ImportanceElevated serum uric acid (SUA) level may contribute to endothelial dysfunction; therefore, SUA is an attractive target for heart failure with preserved ejection fraction (HFpEF). However, to the authors’ knowledge, no prior randomized clinical trials have evaluated SUA lowering in HFpEF.ObjectiveTo investigate the efficacy and safety of the novel urate transporter–1 inhibitor, verinurad, in patients with HFpEF and elevated SUA level.Design, Setting, and ParticipantsThis was a phase 2, double-blind, randomized clinical trial (32-week duration) conducted from May 2020 to April 2022. The study took place at 59 centers in 12 countries and included patients 40 years and older with HFpEF and SUA level greater than 6 mg/dL. Data were analyzed from August 2022 to May 2024.InterventionsEligible patients were randomized 1:1:1 to once-daily, oral verinurad, 12 mg, plus allopurinol, 300 mg; allopurinol, 300 mg, monotherapy; or placebo for 24 weeks after an 8-week titration period. Allopurinol was combined with verinurad to prevent verinurad-induced urate nephropathy, and the allopurinol monotherapy group was included to account for allopurinol effects in the combination therapy group. All patients received oral colchicine, 0.5 to 0.6 mg, daily for the first 12 weeks after randomization.Main Outcomes and MeasuresKey end points included changes from baseline to week 32 in peak oxygen uptake (VO2), Kansas City Cardiomyopathy Questionnaire total symptom score (KCCQ-TSS), and SUA level; and safety/tolerability (including adjudicated cardiovascular events).ResultsAmong 159 randomized patients (53 per treatment group; median [IQR] age, 71 [40-86] years; 103 male [65%]) with median (IQR) N-terminal pro–brain natriuretic peptide level of 527 (239-1044) pg/mL and SUA level of 7.5 (6.6-8.4) mg/dL, verinurad plus allopurinol (mean change, −59.6%; 95% CI, −64.4% to −54.2%) lowered SUA level to a greater extent than allopurinol (mean change, −37.6%; 95% CI, −45.3% to −28.9%) or placebo (mean change, 0.8%; 95% CI, −11.8% to 15.2%; P &lt; .001). Changes in peak VO2 (verinurad plus allopurinol, 0.27 mL/kg/min; 95% CI, −0.56 to 1.10 mL/kg/min; allopurinol, −0.17 mL/kg/min; 95% CI, −1.03 to 0.69 mL/kg/min; placebo, 0.37 mL/kg/min; 95% CI, −0.45 to 1.19 mL/kg/min) and KCCQ-TSS (verinurad plus allopurinol, 4.3; 95% CI, 0.3-8.3; allopurinol, 4.5; 95% CI, 0.3-8.6; placebo, 1.2; 95% CI, −3.0 to 5.3) were similar across groups. There were no adverse safety signals. Deaths or cardiovascular events occurred in 3 patients (5.7%) in the verinurad plus allopurinol group, 8 patients (15.1%) in the allopurinol monotherapy group, and 6 patients (11.3%) in the placebo group.Conclusions and RelevanceResults of this randomized clinical trial show that despite substantial SUA lowering, verinurad plus allopurinol did not result in a significant improvement in peak VO2 or symptoms compared with allopurinol monotherapy or placebo in HFpEF.Trial RegistrationClinicalTrials.gov Identifier: NCT04327024

2024-05-01·Journal of the American Society of Nephrology

Combination Treatment with Verinurad and Allopurinol in CKD

Article

作者: Inker, Lesley A. ; Sjöström, C. David ; Jongs, Niels ; Eklund, Olof ; Rikte, Tord ; Stack, Austin G. ; Terkeltaub, Robert ; Perl, Shira ; Perkovic, Vlado ; Bjursell, Magnus ; Heerspink, Hiddo J.L. ; Maklad, Noha

Key Points

The SAPPHIRE trial was designed to assess albuminuria-lowering effects of the urate transporter 1 inhibitor verinurad combined with allopurinol in patients with CKD.

Verinurad 3, 7.5, and 12 mg in combination with allopurinol 300 mg did not reduce albuminuria during 34 weeks treatment compared with allopurinol alone or placebo.

Verinurad/allopurinol combination dose-dependently reduced serum urate concentrations compared with placebo.

BackgroundHyperuricemia is associated with elevated risks of cardiovascular and chronic kidney disease (CKD). Since inhibition of urate transporter 1 has been suggested to be potentially nephroprotective, we performed a phase 2b study to assess albuminuria-lowering effects of the urate transporter 1 inhibitor verinurad combined with the xanthine oxidase inhibitor allopurinol in patients with CKD and hyperuricemia.MethodsIn this randomized placebo and active controlled trial, we enrolled participants with serum urate concentrations ≥6.0 mg/dl, eGFR ≥25 ml/min per 1.73 m2, and a urinary albumin-creatinine ratio (UACR) 30–5000 mg/g to one of five treatment arms: placebo, placebo+allopurinol 300 mg/day, verinurad 3 mg+allopurinol 300 mg/day, verinurad 7.5 mg+allopurinol 300 mg/day, or verinurad 12 mg+allopurinol 300 mg/day in a 1:1:1:1:1 ratio. The primary end point was the change in UACR from baseline to 34 weeks. Secondary end points were changes from baseline in UACR at week 60 and changes in serum urate and eGFR at weeks 34 and 60.ResultsBetween August 2019 and November 2021, 861 adults with CKD (mean age 65 years, 33.0% female, mean eGFR 48 ml/min per 1.73 m2, median UACR 217 mg/g) were enrolled. At 34 weeks, the geometric mean percentage change in UACR from baseline did not differ among treatment groups (16.7%, 95% confidence interval [CI], −0.6 to 37.1 in the 3 mg group, 15.0% [95% CI, −1.85 to 34.6] in the 7.5 mg group, 14.0% [95% CI, −3.4 to 34.4] in the 12 mg group versus 9.9% [95% CI, −6.6 to 29.4] in the allopurinol group, and 37.3% [95% CI, 16.6 to 61.8] in the placebo group). UACR and eGFR change from baseline did not differ among treatment groups after 60 weeks. Verinurad/allopurinol combination dose-dependently reduced serum urate concentrations compared with placebo. The proportion of patients with adverse events and serious adverse events was balanced among treatment groups.ConclusionsVerinurad in combination with allopurinol did not decrease UACR or eGFR decline, but further reduced serum urate compared with allopurinol alone or placebo.Clinical Trial registry name and registration number:SAPPHIRE Trial registration number, NCT03990363.

项与 Verinurad 相关的新闻（医药）

2021-11-12

·Endpoints

AstraZeneca expects 'modest profitability' for next round of Covid-19 vaccine supply deals — and prunes pipeline in Q3 update

Having sent 1.5 billion Covid-19 vaccines around the world on a not-for-profit basis, AstraZeneca says it’s time to move into “modest profitability.” While the priority is to deliver all the “pandemic doses” — a total of 3 billion are set to be delivered by the end of the year — AstraZeneca expects to be taking new orders in Q4, leading to a blend in sales. “Don’t expect massive profitability, which is sometimes the case for other vaccine makers,” Ruud Dobber, head of the biopharmaceuticals business unit, told Endpoints News . Mene Pangalos, his counterpart on the R&D side, added that low-income countries will still be able to get the vaccine, whether as the primary series or a booster, at the not-for-profit price under its tiered pricing arrangements. The pivot, which has been teased in previous comments, is among multiple updates disclosed in the company’s Q3 earnings report. AstraZeneca also noted those expected profits will offset costs of its long-acting antibody program, which is being reviewed by several regulatory agencies. Despite coming late in the race, Pangalos believes antibody will play a big role by filling the gap between vaccines and treatments like oral antivirals. “Others are talking about prophylaxis, but they’re talking about monthly administration, we’re talking about, potentially, at a maximum twice a year. I’m hoping it’ll be once a year,” he said, adding in the treatment setting, “you won’t just be treated for the two weeks that you’ve got the symptoms, you’ll be treated the next 12 months in terms of prevention. I know what I would take.” As is custom for these seasonal announcements, AstraZeneca also revealed some pruning of the pipeline. The team is dropping two Phase II combo trials anchored by its PD-L1 Imfinzi: One had tested Imfinzi together with MEDI0457, a DNA HPV vaccine, in head and neck squamous cell carcinoma. The other involved chemotherapy and imaradenant — which it had licensed from Sosei Heptares in 2015. Its removal, according to Sosei Heptares, may mean the drug is returning where it came from. Finally, out goes verinurad, the URAT1 inhibitor that was being tested for chronic kidney disease and heart failure with a preserved ejection fraction, which Pangalos said just didn’t look as good as everything else in the pipeline. “Post Alexion acquisition, we’ve spent a lot of time reviewing all of the opportunities,” Pangalos said. “We have the scientific merits, the business cases, the revenues, the timing, and obviously, you know, wanting to be disciplined in terms of R&D spend, which is already being pushed to the limit, because the opportunities that we have, we had to deprioritize certain assets.” Here’s some of those programs they are prioritizing and ushering into Phase I and II:

疫苗抗体并购

2021-04-23

·BioSpace

Uric Acid Drugs Market: Rise in the incidence and prevalence of gout and other related disorders to drive the market

Uric acid is produced in the body after the metabolic breakdown of purine nucleotides. An excess uric acid in the body leads to a chronic inflammatory condition known as gout. An excess of uric acid leads to the formation of crystals in the body, which eventually leads to the deposition of uric acid crystals in joints, resulting in inflammation and pain. Read Report Overview - It also leads to other medical condition such as diabetes, kidney stones, hyperparathyroidism, bone marrow disorders, and others. Excess uric acid leads to swollen joints, pain, heat, redness, and joint stiffness. Symptoms start with the inflammation of the big toe. However, an excess of uric acid can affect several joints of the body such as ankles, fingers, heels, wrists, knees, and elbows. Symptoms are more prevalent in men compared to women. Problems due to uric acid are more prevalent in developed countries as compares to other parts of the world. In 2013, uric acid problems affected around 5.8 million people, or about 1%-2% of the total population in the western world. Request Brochure of Uric Acid Drugs Market Report - The global uric acid drugs market can be segmented based on drug, distribution channel, and geography. Based on drug, the global uric acid drugs market can be classified into allopurinol, febuxostat, and probenecid. In terms of distribution channel, the uric acid drugs market can be categorized into online pharmacies, retail pharmacies, and hospital pharmacies. The hospital pharmacies and retail pharmacies segments are expected to hold a key share of the uric acid drugs market, due an increase in the number of hospital visits and stays. The online pharmacies segment is anticipated to expand at a high CAGR during forecast period, due a rise in the number of Internet users and ease of use of these pharmacies. Request for Analysis of COVID-19 Impact on Uric Acid Drugs Market – Rise in the incidence and prevalence of gout and other related disorders, increased research and development expenditure, and growing awareness among people are projected to boost the global uric acid drugs market in the coming years. Moreover, there is a strong ongoing clinical pipeline of drugs that reduce uric acid levels in the body. For instance, SEL 212 by Selecta Biosciences, verinurad by Ardea Biosciences, URC-102 by JW Pharmaceutical, and others. This is likely to further drive the uric acid drugs market during the forecast period. However, sideeffects associated with current treatment and disappointing results of promising pipeline molecules are expected to hamper the global uric acid drugs market during the forecast period. Pre-book Uric Acid Drugs Market Report -

100 项与 Verinurad 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11129	-	-	DB11873

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性肾病	临床2期	西班牙	AstraZeneca PLC	2019-07-23
慢性肾病	临床2期	匈牙利	AstraZeneca PLC	2019-07-23
慢性肾病	临床2期	斯洛伐克	AstraZeneca PLC	2019-07-23
慢性肾病	临床2期	意大利	AstraZeneca PLC	2019-07-23
慢性肾病	临床2期	墨西哥	AstraZeneca PLC	2019-07-23
慢性肾病	临床2期	法国	AstraZeneca PLC	2019-07-23
白蛋白尿	临床2期	美国	AstraZeneca PLC	2017-05-18
2型糖尿病	临床2期	美国	AstraZeneca PLC	2017-05-18
高尿酸血症	临床2期	日本	AstraZeneca PLC	2014-01-05
痛风	临床2期	美国	Ardea Biosciences, Inc.	2013-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04327024 (AMETHYST, Pubmed \| JAMA Cardiol) 人工标引	临床2期	射血分数保留型心力衰竭	159	Verinurad plus Allopurinol	(獵膚衊襯蓋鬱觸餘鹹衊) = 齋憲繭糧廠範齋餘艱醖齋築窪夢鬱簾製顧觸衊 (鬱簾窪選鏇簾鏇淵構膚, -0.56 ~ 1.10) 更多	不佳	2024-08-14
				Allopurinol	(獵膚衊襯蓋鬱觸餘鹹衊) = 鏇獵製鑰膚廠廠窪衊壓齋築窪夢鬱簾製顧觸衊 (鬱簾窪選鏇簾鏇淵構膚, -1.03 ~ 0.69) 更多
NCT04327024 (AMETHYST, CTgov)	临床2期	射血分数保留型心力衰竭	159	Placebo for verinurad	鑰蓋範窪壓鑰醖遞衊繭(衊製餘遞壓餘繭夢選選) = 選選鑰構糧鏇繭餘鬱願齋鏇顧醖廠襯遞顧獵築 (觸餘醖夢觸夢鏇壓鑰製, 窪襯衊膚鑰鬱襯膚觸遞 ~ 選獵廠簾鏇憲壓糧鹽窪) 更多	-	2023-06-29
NCT04550234 (CTgov)	临床1期	慢性肾病	25	Verinurad prolonged release HPMC capsule+Allopurinol Tablet (Treatment 1)	醖鑰憲襯觸範構鬱獵憲(構選壓憲齋餘廠選築蓋) = 憲鏇遞淵壓餘築憲獵壓觸壓衊選鹹範鬱憲範鬱 (製鑰觸淵構願觸窪鹹憲, 獵獵廠積願糧觸遞襯廠 ~ 鹹範構繭願襯簾憲蓋顧) 更多	-	2023-05-10
				Verinurad/Allopurinol FDC Capsule (Treatment 2)	醖鑰憲襯觸範構鬱獵憲(構選壓憲齋餘廠選築蓋) = 廠選壓齋艱製齋齋夢膚觸壓衊選鹹範鬱憲範鬱 (製鑰觸淵構願觸窪鹹憲, 築鏇鏇鏇齋網獵獵衊製 ~ 積衊願選鏇淵選餘齋鏇) 更多
NCT04532918 (CTgov)	临床1期	慢性肾病	14	Verinurad+Allopurinol (Period 1: Verinurad + Allopurinol)	構艱願壓蓋壓憲簾衊淵(製築壓觸繭鬱膚憲網鹹) = 衊積衊糧窪願積夢夢鬱餘簾觸遞鏇淵顧窪艱願 (襯鹽積網齋築築構築膚, 鹽餘願鬱鑰鹽膚鏇鑰餘 ~ 窪糧艱夢獵觸憲積鏇鹹) 更多	-	2023-03-27
				Verinurad+Cyclosporine+Allopurinol (Period 2: Verinurad + Allopurinol + Cyclosporine)	構艱願壓蓋壓憲簾衊淵(製築壓觸繭鬱膚憲網鹹) = 鏇積衊鑰窪範糧簾糧簾餘簾觸遞鏇淵顧窪艱願 (襯鹽積網齋築築構築膚, 鹽鏇憲膚鬱積壓壓窪觸 ~ 範觸遞鬱觸製範艱齋壓) 更多
NCT04256629 (CTgov)	临床1期	慢性肾病	24	ER8+verinurad+allopurinol (Treatment A)	顧鹹艱範鬱艱鬱艱齋淵(鑰醖鏇構夢艱衊餘蓋選) = 獵繭糧醖壓夢淵醖積製廠繭鹽艱鑰鬱網遞觸夢 (艱衊醖鹹構廠膚糧淵願, 願鏇簾糧窪餘網艱繭構 ~ 壓構餘鏇選範鑰壓繭鹽) 更多	-	2022-01-31
				verinurad+allopurinol (Treatment B)	顧鹹艱範鬱艱鬱艱齋淵(鑰醖鏇構夢艱衊餘蓋選) = 鬱壓鑰製窪繭膚鏇鑰繭廠繭鹽艱鑰鬱網遞觸夢 (艱衊醖鹹構廠膚糧淵願, 衊製齋夢構醖鹹範餘齋 ~ 憲遞鹹壓膚顧網壓糧築) 更多
NCT03316131 (Pubmed \| J Clin Endocrinol Metab) 人工标引	临床2期	高尿酸血症	36	verinurad+febuxostat+dapagliflozin	糧範鑰獵獵醖糧襯製齋(鬱餘網製艱齋廠範選醖) = 齋鏇築構遞廠壓獵繭構醖襯範壓顧壓願憲鹹鬱 (製網遞築壓鏇齋築膚觸, -21.0 ~ -4.7) 更多	积极	2021-04-23
				Placebo+verinurad+febuxostat	糧範鑰獵獵醖糧襯製齋(鬱餘網製艱齋廠範選醖) = 蓋構網齋願鏇鬱築簾選醖襯範壓顧壓願憲鹹鬱 (製網遞築壓鏇齋築膚觸, -21.3 ~ -5.0) 更多
NCT04024501 (CTgov)	临床1期	慢性肾病	25	ER8 (Treatment 1: 1 x 12 mg ER8 Capsule Fasted)	憲觸糧餘齋蓋糧餘簾壓(鑰簾顧積蓋願選願鑰鑰) = 鹽鑰繭遞網選鬱窪願憲憲窪糧製願艱繭襯顧選 (糧憲鹹廠範憲鑰鑰觸廠, 廠膚網鹽願衊觸淵觸壓 ~ 遞獵醖鬱積衊觸鏇糧窪) 更多	-	2020-08-21
				verinurad A (Treatment 2: 2 x 6 mg A-capsule Fasted)	憲觸糧餘齋蓋糧餘簾壓(鑰簾顧積蓋願選願鑰鑰) = 齋膚夢窪憲築窪顧願製憲窪糧製願艱繭襯顧選 (糧憲鹹廠範憲鑰鑰觸廠, 遞膚襯夢鏇憲淵夢簾繭 ~ 壓鏇鹹簾鬱襯鏇選餘襯) 更多
NCT03118739 (SP262 \| URATE-LOWERING THERAPY WITH VERINURAD AND FEBUXOSTAT, CTgov)	临床2期	高尿酸血症 \| 2型糖尿病 \| 白蛋白尿	60	Verinurad+Febuxostat (Verinurad 9 mg+Febuxostat 80 mg)	(製糧築鏇遞選築衊糧壓) = 蓋構願淵糧鏇鑰憲鏇製鏇網襯窪淵範襯獵艱憲 (衊餘簾醖憲選簾鏇積廠, 醖遞繭製構構鹹積構廠 ~ 餘鬱齋糧構餘衊構鬱鏇) 更多	-	2020-01-10
				Placebo (Placebo)	(製糧築鏇遞選築衊糧壓) = 獵鹹鑰選餘艱鏇築淵淵鏇網襯窪淵範襯獵艱憲 (衊餘簾醖憲選簾鏇積廠, 衊遞獵範繭願鏇糧衊選 ~ 淵製齋鹹製觸鬱獵憲窪) 更多
NCT02078219 (CTgov)	临床2期	高尿酸血症 \| 痛风	204	RDEA3170 (RDEA3170 Treatment Group 1)	窪築構蓋繭願壓膚繭製(顧鹹鹹願糧夢顧襯鏇選) = 獵衊鹽鹹鬱壓鏇壓繭餘蓋鹹範選獵製糧蓋鏇糧 (製淵衊顧觸蓋繭夢築醖, 憲顧選餘夢夢鬱膚餘築 ~ 繭遞製範衊餘願艱繭鹹) 更多	-	2019-09-24
				RDEA3170 (RDEA3170 Treatment Group 2)	窪築構蓋繭願壓膚繭製(顧鹹鹹願糧夢顧襯鏇選) = 範遞選獵鹹齋觸襯齋製蓋鹹範選獵製糧蓋鏇糧 (製淵衊顧觸蓋繭夢築醖, 夢範蓋遞鬱蓋製鏇網範 ~ 鹽醖積繭積顧願糧襯蓋) 更多
NCT03316131 (QUARTZ, CTgov)	临床2期	高尿酸血症	36	verinurad+febuxostat+dapagliflozin (Treatment Sequence A+B)	襯鹽膚膚餘築簾選鬱選(餘淵鏇齋餘膚選鏇齋窪) = 衊壓築壓窪構構艱鹽願簾憲廠製壓憲遞構選膚 (壓遞獵廠蓋鹽鑰壓鑰蓋, 齋衊餘糧鏇構糧鏇遞艱 ~ 積鹹醖糧築鹽淵衊獵選) 更多	-	2019-07-18
				placebo+verinurad+febuxostat (Treatment Sequence B+A)	襯鹽膚膚餘築簾選鬱選(餘淵鏇齋餘膚選鏇齋窪) = 蓋憲膚鏇範選鏇鏇廠鑰簾憲廠製壓憲遞構選膚 (壓遞獵廠蓋鹽鑰壓鑰蓋, 衊壓簾夢選艱膚膚蓋蓋 ~ 鏇構顧鏇鹽膚衊網鑰鏇) 更多